Core Technology:
Tetratherix has developed a proprietary fluid matrix called Tetramatrix, which is a water-based polymer solution that forms an adhesive hydrogel upon administration.
Applications:
Their technology is being developed for various applications, including bone reconstruction, cartilage regeneration, and targeted drug delivery.
Commercialisation:
Tetratherix is focused on commercialising their Tetramatrix platform technology and developing products for specific indications.
Business Model:
Tetratherix utilizes a contemporary commercial model, drawing inspiration from the technology and software industries, and is building a global supply of products derived from its platform technology at scale.
Funding and Growth:
The company has secured funding from various sources, including private and public investments and venture capital groups like Ryder Innovation Fund. They have also executed co-development licensing agreements with pharmaceutical companies to expand their market reach, including an agreement with a leading Chinese pharmaceutical company.
Focus on Regenerative Medicine:
Tetratherix aims to leverage its biopolymers to improve regenerative medicine by enabling the body’s own healing processes.
Global Presence:
Tetratherix is expanding its global presence, with plans to develop and market products in key markets like China.
ASX Listing:
Tetratherix launched its IPO on the Australian Securities Exchange (ASX) in May 2025.
Team and Expertise:
Tetratherix has a team with expertise in advanced chemistry production and commercialization. They also have an advisory board with key figures in the biomedicine field.
It is anticipated that TTX will list on the ASX on 30 June 2025.
